|
1
|
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan
HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al:
Asian-pacific clinical practice guidelines on the management of
hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xue X, Cai S, Ou H, Zheng C and Wu X:
Health-related quality of life in patients with chronic hepatitis B
during antiviral treatment and off-treatment. Patient Prefer
Adherence. 11:85–93. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu X, Cai S, Li Z, Zheng C, Xue X, Zeng J
and Peng J: Potential effects of telbivudine and entecavir on renal
function: A systematic review and meta-analysis. Virol J.
13:642016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peng J, Yin J, Cai S, Yu T and Zhong C:
Factors associated with adherence to nucleos(t)ide analogs in
chronic hepatitis B patients: Results from a 1 year follow-up
study. Patient Prefer Adherence. 9:41–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lok AS and McMahon BJ: Chronic hepatitis
b: Update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gutierrez-Fisac JL, Guallar-Castillon P,
Leon-Munoz LM, Graciani A, Banegas JR and Rodriguez-Artalejo F:
Prevalence of general and abdominal obesity in the adult population
of Spain, 2008–2010: The ENRICA study. Obes Rev. 13:388–392. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhai Y, Fang HY, Yu WT, Yu DM, Zhao LY,
Liang XF and Zhao WH: Changes in waist circumference and abdominal
obesity among chinese adults over a ten-year period. Biomed Environ
Sci. 30:315–322. 2017.PubMed/NCBI
|
|
8
|
Suder A, Janusz M, Jagielski P, Głodzik J,
Pałka T, Cisoń T and Pilch W: Prevalence and risk factors of
abdominal obesity in polish rural children. Homo. 66:357–368. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim J and Park HS: Trends in the
prevalence of underweight, obesity, abdominal obesity and their
related lifestyle factors in korean young adults, 1998–2012. Obes
Res Clin Pract. 12:358–364. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai S, Ou Z, Liu D, Liu L, Liu Y, Wu X, Yu
T and Peng J: Risk factors associated with liver steatosis and
fibrosis in chronic hepatitis B patient with component of metabolic
syndrome. United European Gastroenterol J. 6:558–566. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ou H, Cai S, Liu Y, Xia M and Peng J: A
noninvasive diagnostic model to assess nonalcoholic hepatic
steatosis in patients with chronic hepatitis B. Therap Adv
Gastroenterol. 10:207–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
European Association for the Study of the
Liver (EASL) European Association for the Study of Diabetes (EASD),
European Association for the Study of Obesity (EASO), :
EASL-EASD-EASO clinical practice guidelines for the management of
non-alcoholic fatty liver disease. J Hepatol. 64:1388–1402. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Besharat S, Poustchi H, Mohamadkhani A,
Roshandel G, Freedman ND, Merat S and Malekzadeh R: Central obesity
and advanced liver stiffness in hepatitis b: Result from golestan
hepatitis b cohort study. Arch Iran Med. 18:562–566.
2015.PubMed/NCBI
|
|
14
|
Wong L, Chan HL, Yu Z, Chan AW, Choi PC,
Chim AM, Chan HY, Tse CH and Wong VW: Coincidental metabolic
syndrome increases the risk of liver fibrosis progression in
patients with chronic hepatitis B-a prospective cohort study with
paired transient elastography examinations. Aliment Pharmacol Ther.
39:883–893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alberti KG, Zimmet P and Shaw J: The
metabolic syndrome-a new worldwide definition. Lancet.
366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen YP, Liang XE, Zhang Q, Peng J, Zhu
YF, Wen WQ and Hou JL: Larger biopsies evaluation of transient
elastography for detecting advanced fibrosis in patients with
compensated chronic hepatitis B. J Gastroenterol Hepatol.
27:1219–1226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai S, Cao J, Yu T, Xia M and Peng J:
Effectiveness of entecavir or telbivudine therapy in patients with
chronic hepatitis B virus infection pre-treated with interferon
compared with de novo therapy with entecavir and telbivudine.
Medicine (Baltimore). 96:e70212017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xue X and Cai S: Comment on ‘assessment of
liver stiffness in pediatric fontan patients using transient
elastography’. Can J Gastroenterol Hepatol. 2016:93439602016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai S, Yu T, Jiang Y, Zhang Y, Lv F and
Peng J: Comparison of entecavir monotherapy and de novo lamivudine
and adefovir combination therapy in HBeAg-positive chronic
hepatitis B with high viral load: 48 week result. Clin Exp Med.
16:429–436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cai SH, Lv FF, Zhang YH, Jiang YG and Peng
J: Dynamic comparison between daan real-time PCR and cobas taqman
for quantification of HBV DNA levels in patients with Chb. Bmc
Infect Dis. 14:852014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng J, Cai S, Liu J, Xue X, Wu X and
Zheng C: Dynamic changes in liver stiffness measured by transient
elastography predict clinical outcomes among patients with chronic
hepatitis b. J Ultrasound Med. 36:261–268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cai SH, Lu SX, Liu LL, Zhang CZ and Yun
JP: Increased expression of hepatocyte nuclear factor 4 alpha
transcribed by promoter 2 indicates a poor prognosis in
hepatocellular carcinoma. Therap Adv Gastroenterol. 10:761–771.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH,
Wang H, Cai SH, Yang X, Xie D, Zhang CZ and Yun JP: HBx-mediated
decrease of AIM2 contributes to hepatocellular carcinoma
metastasis. Mol Oncol. 11:1225–1240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai S, Li Z, Yu T, Xia M and Peng J: Serum
hepatitis B core antibody levels predict HBeAg seroconversion in
chronic hepatitis B patients with high viral load treated with
nucleos(t)ide analogs. Infect Drug Resist. 11:469–477. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roulot D, Roudot-Thoraval F, Nkontchou G,
Kouacou N, Costes JL, Elourimi G, Le Clesiau H, Ziol M and
Beaugrand M: Concomitant screening for liver fibrosis and steatosis
in french type 2 diabetic patients using Fibroscan. Liver Int.
37:1897–1906. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peng J, Cai S, Yu T, Chen Y, Zhu Y and Sun
J: Aspartate aminotransferase to platelet ratio index - a reliable
predictor of therapeutic efficacy and improvement of Ishak score in
chronic hepatitis B patients treated with nucleoside analogues.
Scand J Clin Lab Invest. 76:133–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Corpechot C, Gaouar F, Chretien Y, Johanet
C, Chazouilleres O and Poupon R: Smoking as an independent risk
factor of liver fibrosis in primary biliary cirrhosis. J Hepatol.
56:218–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van der Vaart H, Postma DS, Timens W and
Ten HN: Acute effects of cigarette smoke on inflammation and
oxidative stress: A review. Thorax. 59:713–721. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bijl M, Horst G, Limburg PC and Kallenberg
CG: Effects of smoking on activation markers, Fas expression and
apoptosis of peripheral blood lymphocytes. Eur J Clin Invest.
31:550–553. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zeidel A, Beilin B, Yardeni I, Mayburd E,
Smirnov G and Bessler H: Immune response in asymptomatic smokers.
Acta Anaesthesiol Scand. 46:959–964. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma Z, Hou T, Shi W, Liu W and He H:
Inhibition of hepatocyte apoptosis: An important mechanism of corn
peptides attenuating liver injury induced by ethanol. Int J Mol
Sci. 16:22062–22080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim WH, Hong F, Jaruga B, Hu Z, Fan S,
Liang TJ and Gao B: Additive activation of hepatic NF-kappaB by
ethanol and hepatitis B protein X (HBX) or HCV core protein:
Involvement of TNF-alpha receptor 1-independent and -dependent
mechanisms. FASEB J. 15:2551–2553. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiao YB, Cai SH, Liu LL, Yang X and Yun
JP: Decreased expression of peroxisome proliferator-activated
receptor alpha indicates unfavorable outcomes in hepatocellular
carcinoma. Cancer Manag Res. 10:1781–1789. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin X, Chen YP, Yang YD, Li YM, Zheng L
and Xu CQ: Association between hepatic steatosis and entecavir
treatment failure in Chinese patients with chronic hepatitis B.
PLoS One. 7:e341982012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chan AW, Wong GL, Chan HY, Tong JH, Yu YH,
Choi PC, Chan HL, To KF and Wong VW: Concurrent fatty liver
increases risk of hepatocellular carcinoma among patients with
chronic hepatitis B. J Gastroenterol Hepatol. 32:667–676. 2017.
View Article : Google Scholar : PubMed/NCBI
|
